The Core Thesis: Structural Shift to Leadership
NATCO Pharma has successfully completed a massive Stage 1 accumulation base (range between ₹795–₹1,030) and is now entering a high-probability Stage 2 advancing phase. This transition is backed by a significant "Change of Character" (CHoCH) and multiple "Break of Structure" (BOS) levels, indicating that institutional demand has firmly overtaken supply.
Technical Breakdown
Moving Average Mastery: The stock is trading in a perfect bullish alignment. It is held firmly above the 10, 20, and 50-week EMAs, with the long-term 200-week SMA trending upward, providing a deep structural floor.
Relative Strength (RS): As noted on the chart, the Relative Strength has turned decisively positive. This upward trajectory in the green zone confirms that NATCO is outperforming the broader Nifty index, marking it as a sectoral leader.
Volume Footprint: There is clear evidence of high volume near the demand zone, suggesting heavy accumulation during the base formation. The recent consolidation near ₹1,093 is occurring on lower volume, which typically signals a "pause that refreshes" before the next leg up.
Current Pattern: The stock is currently consolidating just above the primary breakout point (₹1,030). This retest of the previous "ceiling" now acting as a "floor" is a classic entry signal for trend followers.
Tactical Trade Plan
Entry Range: ₹1,050 – ₹1,100 (Accumulate during the current consolidation).
Stop-Loss (SL): ₹980 (Weekly close basis). This protects you below the 50-week EMA and the recent structural breakout zone.
Target 1: ₹1,350 (Test of the previous major supply zone/red band).
Target 2: ₹1,600+ (Test of the historical "Weak High").
Final Note for Traders
NATCO Pharma is a textbook example of a stock moving from Stage 1 (Base) to Stage 2 (Trend). The combination of a multi-month base breakout, positive RS, and strong volume support at the floor makes this a high-conviction swing setup.
Disclaimer: For educational purposes only. Always manage your risk.
NATCO Pharma has successfully completed a massive Stage 1 accumulation base (range between ₹795–₹1,030) and is now entering a high-probability Stage 2 advancing phase. This transition is backed by a significant "Change of Character" (CHoCH) and multiple "Break of Structure" (BOS) levels, indicating that institutional demand has firmly overtaken supply.
Technical Breakdown
Moving Average Mastery: The stock is trading in a perfect bullish alignment. It is held firmly above the 10, 20, and 50-week EMAs, with the long-term 200-week SMA trending upward, providing a deep structural floor.
Relative Strength (RS): As noted on the chart, the Relative Strength has turned decisively positive. This upward trajectory in the green zone confirms that NATCO is outperforming the broader Nifty index, marking it as a sectoral leader.
Volume Footprint: There is clear evidence of high volume near the demand zone, suggesting heavy accumulation during the base formation. The recent consolidation near ₹1,093 is occurring on lower volume, which typically signals a "pause that refreshes" before the next leg up.
Current Pattern: The stock is currently consolidating just above the primary breakout point (₹1,030). This retest of the previous "ceiling" now acting as a "floor" is a classic entry signal for trend followers.
Tactical Trade Plan
Entry Range: ₹1,050 – ₹1,100 (Accumulate during the current consolidation).
Stop-Loss (SL): ₹980 (Weekly close basis). This protects you below the 50-week EMA and the recent structural breakout zone.
Target 1: ₹1,350 (Test of the previous major supply zone/red band).
Target 2: ₹1,600+ (Test of the historical "Weak High").
Final Note for Traders
NATCO Pharma is a textbook example of a stock moving from Stage 1 (Base) to Stage 2 (Trend). The combination of a multi-month base breakout, positive RS, and strong volume support at the floor makes this a high-conviction swing setup.
Disclaimer: For educational purposes only. Always manage your risk.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.